TuHURA Biosciences’ (HURA) Buy Rating Reiterated at HC Wainwright

TuHURA Biosciences (NASDAQ:HURA)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 price target on the stock.

Several other equities research analysts have also commented on the stock. Maxim Group lowered their price target on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 14th. Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, December 14th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Trading Down 3.0%

Shares of NASDAQ:HURA opened at $0.52 on Tuesday. TuHURA Biosciences has a twelve month low of $0.50 and a twelve month high of $5.03. The company’s 50 day moving average is $1.01 and its 200 day moving average is $1.99. The company has a market cap of $26.60 million, a PE ratio of -1.04 and a beta of 0.12.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01.

Hedge Funds Weigh In On TuHURA Biosciences

Large investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in shares of TuHURA Biosciences in the third quarter worth approximately $26,000. Vanguard Group Inc. raised its stake in TuHURA Biosciences by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock valued at $5,629,000 after purchasing an additional 35,426 shares during the last quarter. PFG Investments LLC acquired a new stake in TuHURA Biosciences during the 3rd quarter worth $58,000. SG Americas Securities LLC purchased a new stake in shares of TuHURA Biosciences during the third quarter worth $41,000. Finally, Apollon Wealth Management LLC raised its position in shares of TuHURA Biosciences by 15.8% in the third quarter. Apollon Wealth Management LLC now owns 133,526 shares of the company’s stock valued at $331,000 after buying an additional 18,252 shares during the last quarter. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.